Resistance Mechanisms to Anti-PD Cancer Immunotherapy DOI
Matthew D. Vesely,

Tianxiang Zhang,

Lieping Chen

et al.

Annual Review of Immunology, Journal Year: 2022, Volume and Issue: 40(1), P. 45 - 74

Published: April 26, 2022

The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1 (B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However, only a fraction patients with solid tumors and some hematopoietic malignancies respond to anti-PD therapy, reason for failure in other is less known. By dissecting mechanisms underlying this resistance, current studies reveal that tumor microenvironment major location resistance occur. Furthermore, appear be highly heterogeneous. Here, we discuss recent human data identifying therapy. We review evidence immune-based such as loss neoantigens, defects antigen presentation interferon signaling, immune inhibitory molecules, exclusion T cells. also clinical emerging alterations metabolism, microbiota, epigenetics. Finally, strategies overcome therapy emphasize need develop additional immunotherapies based on concept normalization immunotherapy.

Language: Английский

Single-cell reconstruction of the early maternal–fetal interface in humans DOI

Roser Vento‐Tormo,

Mirjana Efremova, Rachel A. Botting

et al.

Nature, Journal Year: 2018, Volume and Issue: 563(7731), P. 347 - 353

Published: Nov. 8, 2018

Language: Английский

Citations

1898
Cancer immunoediting and resistance to T cell-based immunotherapy DOI
Jake S. O’Donnell, Michele W.L. Teng, Mark J. Smyth

et al.

Nature Reviews Clinical Oncology, Journal Year: 2018, Volume and Issue: 16(3), P. 151 - 167

Published: Dec. 6, 2018

Language: Английский

Citations

1450
Macrophages and Metabolism in the Tumor Microenvironment DOI Creative Commons
Ilio Vitale, Gwenola Manic, Lisa M. Coussens

et al.

Cell Metabolism, Journal Year: 2019, Volume and Issue: 30(1), P. 36 - 50

Published: July 1, 2019

Language: Английский

Citations

1368
CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review DOI
Bagher Farhood, Masoud Najafi, Keywan Mortezaee

et al.

Journal of Cellular Physiology, Journal Year: 2018, Volume and Issue: 234(6), P. 8509 - 8521

Published: Nov. 22, 2018

CD8+ cytotoxic T lymphocytes (CTLs) are preferred immune cells for targeting cancer. During cancer progression, CTLs encounter dysfunction and exhaustion due to immunerelated tolerance immunosuppression within the tumor microenvironment (TME), with all favor adaptive immune-resistance. Cancer-associated fibroblasts (CAFs), macrophage type 2 (M2) cells, regulatory (Tregs) could make immunologic barriers against CD8 + cell-mediated antitumor responses. Thus, needed be primed activated toward effector in a process called immunity cycle making durable efficient The cell priming is directed essentially as corroboration work between of innate including dendritic (DCs) natural killer (NK) CD4 adoptive immunity. Upon activation, infiltrate core or invading site (so-called infiltrated-inflamed [I-I] TME) take essential roles killing cells. Exogenous reactivation and/or can possible using rational immunotherapy strategies. increase ratio costimulatory coinhibitory mediators checkpoint blockade (ICB) approach. Programmed death-1 receptor (PD-1)-ligand (PD-L1) CTL-associated antigen 4 (CTLA-4) receptors that targeted relieving renewing their priming, respectively, thereby eliminating antigen-expressing Due diverse relation Tregs, Treg activity dampened increasing number rescuing functional potential induce immunosensitivity

Language: Английский

Citations

1333
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death DOI Creative Commons
Lorenzo Galluzzi, Ilio Vitale, Sarah H. Warren

et al.

Journal for ImmunoTherapy of Cancer, Journal Year: 2020, Volume and Issue: 8(1), P. e000337 - e000337

Published: March 1, 2020

Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular microenvironmental features determine the propensity of RCD drive immunity. Here, we provide updated operational definition immunogenic (ICD), discuss key factors that dictate ability dying cells response, summarize experimental assays are currently available for assessment ICD in vitro vivo, formulate guidelines their interpretation.

Language: Английский

Citations

871
Turning Cold into Hot: Firing up the Tumor Microenvironment DOI Open Access

Qianqian Duan,

Hualing Zhang, Junnian Zheng

et al.

Trends in cancer, Journal Year: 2020, Volume and Issue: 6(7), P. 605 - 618

Published: March 21, 2020

Language: Английский

Citations

744
Next generation of immune checkpoint therapy in cancer: new developments and challenges DOI Creative Commons
Julian A. Marin‐Acevedo, Bhagirathbhai Dholaria, Aixa Soyano

et al.

Journal of Hematology & Oncology, Journal Year: 2018, Volume and Issue: 11(1)

Published: March 15, 2018

Immune checkpoints consist of inhibitory and stimulatory pathways that maintain self-tolerance assist with immune response. In cancer, checkpoint are often activated to inhibit the nascent anti-tumor therapies act by blocking or stimulating these enhance body’s immunological activity against tumors. Cytotoxic T lymphocyte-associated molecule-4 (CTLA-4), programmed cell death receptor-1 (PD-1), ligand-1(PD-L1) most widely studied recognized pathways. Drugs currently utilized for a wide variety malignancies have demonstrated durable clinical activities in subset cancer patients. This approach is rapidly extending beyond CTLA-4 PD-1/PD-L1. New under investigation, drugs LAG-3, TIM-3, TIGIT, VISTA, B7/H3 being investigated. Furthermore, agonists such as OX40, ICOS, GITR, 4-1BB, CD40, molecules targeting tumor microenvironment components like IDO TLR investigation. this article, we provided comprehensive review involved immunotherapy, discuss their mechanisms therapeutic interventions investigation phase I/II trials. We also reviewed limitations, toxicities, challenges outline possible future research directions.

Language: Английский

Citations

709
Extracellular ATP and P2 purinergic signalling in the tumour microenvironment DOI
Francesco Di Virgilio, Alba Clara Sarti, Simonetta Falzoni

et al.

Nature reviews. Cancer, Journal Year: 2018, Volume and Issue: 18(10), P. 601 - 618

Published: July 13, 2018

Language: Английский

Citations

599
Navigating metabolic pathways to enhance antitumour immunity and immunotherapy DOI
Xiaoyun Li, Mathias Wenes, Pedro Romero

et al.

Nature Reviews Clinical Oncology, Journal Year: 2019, Volume and Issue: 16(7), P. 425 - 441

Published: March 26, 2019

Language: Английский

Citations

584
Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer DOI Creative Commons
Kai Li,

Houhui Shi,

Benxia Zhang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2021, Volume and Issue: 6(1)

Published: Oct. 7, 2021

Abstract Myeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature myeloid with immunosuppressive effects, which undergo massive expansion during tumor progression. These not only support immune escape directly but also promote invasion via various non-immunological activities. Besides, this group proved to impair the efficiency current antitumor strategies such as chemotherapy, radiotherapy, and immunotherapy. Therefore, MDSCs considered potential therapeutic targets for cancer therapy. Treatment targeting have shown promising outcomes in both preclinical studies clinical trials when administrated alone, or combination other anticancer therapies. In review, we shed new light on recent advances biological characteristics functions MDSCs. We hope propose an overview MDSCs-targeting therapies so provide ideas treatment.

Language: Английский

Citations

547